Kiniksa Pharmaceuticals announced positive data from the phase 3 RHAPSODY trial evaluating rilonacept for the treatment of recurrent pericarditis. Kiniksa Pharmaceuticals announced positive data from ...

PHILADELPHIA — Rilonacept in patients with recurrent pericarditis led to improvements in clinical and patient-reported measures as soon as after the first injection, according to data presented at the ...

Adult- SC- The recommended loading dose is 160mg twice a day in different sites. Maintenance: 160 mg as single 2 mL injections. Child- SC- The recommended loading dose is 4.4mg/kg. Caution should be ...

Rilonacept is an interleukin-1 (IL-1) blocker, prescribed for Cryopyrin-Associated Periodic Syndromes ((CAPS) - inherited auto-inflammatory conditions) including Familial Cold Autoinflammatory ...

Rilonacept, an interleukin (IL)-1 inhibitor, produces rapid resolution of recurrent pericarditis and fewer recurrent pericarditis episodes among patients who initially respond to drug therapy, as ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

June 6, 2011 (London, United Kingdom) — Rilonacept, an interleukin 1 (IL-1) inhibitor, prevented gout flares to a greater extent in patients receiving uric acid–lowering therapy (specifically, ...

TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...

A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1, significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced it approved rilonacept injection to treat and reduce risk for recurrent pericarditis in adults ...

HealthDay News—The use of rilonacept significantly reduces gout flare-ups in the first few months following initiation of urate-lowering therapy (ULT), according to research published online Jan. 4 in ...